International Clinical Trial: Phase I Clinical Trial on the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) in Subjects Aged 40 Years and Above

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119810) titled 'Phase I Clinical Trial on the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) in Subjects Aged 40 Years and Above' on March 4.

Study Type: Prevention

Study Design: Parallel

Primary Sponsor: Hubei Provincial Center for Disease Control and Prevention

Condition: Prevention of herpes zoster

Intervention: Recombinant varicella-zoster vaccine (CHO cells) (low-dose adjuvant) Group:ecombinant varicella-zoster virus glycoprotein E (gE) 50 µg + low-dose adjuvant system Recombinant varicella-zoster vaccine (CHO cells) (high-dose adjuvant) Group:Recombinant varicella-zoster virus glycop...